biostudies-literatureUnknown40(5)Zappasodi PThe impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson CHematological oncology846-856https://www.ebi.ac.uk/biostudies/studies/S-EPMC9349965biostudies-literatureSecondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.PMC9349965Mina RMaria Vannucchi ABillio ATosi PMassaia MMerli FZerbi CMarchesi FChiara Tisi MMassimo Lemoli RLuppi MITA-HEMA-COV InvestigatorsCoviello ECairoli RFalini BGentile MLanza FStefano Fracchiolla NVenditti AValeria Ferretti VFerrari JGiuliani NRomano APagano LBruno RArcaini LPinto AGalimberti SRigacci LOberti MCattaneo CCuneo ACorso ACavo MTrentin LGiovanni Della Porta MCorradini PMaria Scattolin AMohamed SBusca AAntonio Grossi PSalvini MMarasco VMusto PTafuri ABocchia MMorotti ABertu LJose Maria Ferreri AGherlinzoni FTurrini MZappasodi PPassamonti FKrampera MGambacorti-Passerini CfalseSecondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV.The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson C2022-01-01T00:00:00Z2022 Dec2026-07-14T17:38:42.193Z2024-11-21T01:27:21.873ZS-EPMC93499653585464310.1002/hon.3048